» Articles » PMID: 23355537

How I Assess Comorbidities Before Hematopoietic Cell Transplantation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2013 Jan 29
PMID 23355537
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a comorbidity tool suited for recipients of HCT. The index has been shown to sensitively capture the prevalence and magnitude of severity of various organ impairments before HCT and to provide valuable prognostic information after HCT. Many investigators have validated the discriminative power of the HCT-CI, but others have not. One concern is the consistency in comorbidity coding across different evaluators, particularly in view of the relatively recent addition of the HCT-CI to the transplant evaluation process. In this article, comorbidity scoring was tested across different evaluators, and only a fair interobserver agreement rate could be detected. To address these issues, a brief training program is proposed here, consisting of systematic methodology for data acquisition and consistent guidelines for comorbidity coding that were summarized in a Web-based calculator. In a validation patient cohort, this training program was shown to improve the interevaluator agreement on HCT-CI scores to an excellent rate with weighted κ values in the range of 0.89 to 0.97. This proposed training program will facilitate reliable assessment of comorbidities in the clinic and for research studies leading to standardization of the use of comorbidities in prediction of HCT outcomes.

Citing Articles

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.

Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F Cancers (Basel). 2025; 17(2).

PMID: 39858092 PMC: 11763395. DOI: 10.3390/cancers17020310.


Factors affecting pretransplant muscle strength in allogeneic stem cell transplant candidates prior transplantation.

Limbach M, Kuehl R, Koeppel M, Dreger P, Luft T, Bohus M Support Care Cancer. 2025; 33(2):89.

PMID: 39794666 PMC: 11723852. DOI: 10.1007/s00520-024-09140-8.


Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.

Solis-Armenta R, Rodriguez-Rodriguez S, Hernandez-Perez A, Paulina-Zapata N, Delgado N, Montano-Figueroa E Ann Hematol. 2024; 103(10):4089-4097.

PMID: 39177797 DOI: 10.1007/s00277-024-05956-w.


Nephrons and non-relapse mortality: simplified comorbidity index and acute kidney injury are associated with NRM in adults undergoing allogeneic hematopoietic cell transplant.

Robinson C, Habib A, Klomjit N, Cao Q, Holtan S Front Transplant. 2024; 3:1352413.

PMID: 38993762 PMC: 11235361. DOI: 10.3389/frtra.2024.1352413.


Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH).

Pidala J, Carpenter P, Onstad L, Pavletic S, Hamilton B, Chen G PLoS One. 2024; 19(5):e0298026.

PMID: 38753616 PMC: 11098321. DOI: 10.1371/journal.pone.0298026.


References
1.
van Spronsen D, Janssen-Heijnen M, Breed W, Coebergh J . Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999; 78(7):315-9. DOI: 10.1007/s002770050521. View

2.
Extermann M, Overcash J, Lyman G, Parr J, Balducci L . Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4):1582-7. DOI: 10.1200/JCO.1998.16.4.1582. View

3.
Cotes J, Dabbs J, Elwood P, Hall A, McDonald A, Saunders M . Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci. 1972; 42(3):325-35. DOI: 10.1042/cs0420325. View

4.
Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

5.
Majhail N, Brunstein C, Tomblyn M, Thomas A, Miller J, Arora M . Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008; 14(3):282-9. PMC: 2674378. DOI: 10.1016/j.bbmt.2007.12.488. View